Predictive and Prognostic Roles of <i>BRAF</i> Mutation in Stage III Colon Cancer: Results from Intergroup Trial CALGB 89803

2011266 citationsJournal Articlegreen Open Access

Authors

Shuji Ogino · Memorial Sloan Kettering Cancer Center

Kaori Shima · Loyola University Chicago

Jeffrey A. Meyerhardt · Duke University Hospital

Nadine J. McCleary · Brigham and Women's Hospital

Kimmie Ng · University of North Carolina at Chapel Hill

Donna Hollis · Duke University Hospital

Leonard B. Saltz

Abstract

BRAF mutation is associated with inferior survival in stage III colon cancer. Additional studies are necessary to assess whether there is any predictive role of BRAF mutation for irinotecan-based therapy.

Topics & Keywords

Colorectal Cancer Treatments and Studies Genetic factors in colorectal cancer Colorectal Cancer Surgical Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Cancer Research

Volume 18, Issue 3, pp. 890-900

DOI: 10.1158/1078-0432.ccr-11-2246

Field-Weighted Citation Impact: 13.03